This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV0904

Depresyonda D sikloserin eklenmiş hızlandırılmış aralıklı teta patlaması uyarımı (AIDA-DEP): çalışma protokolü (D-cycloserine-augmented accelerated intermittent theta burst stimulation in depression [AIDA-DEP]: study protocol)

ACCELERATED INTERMITTENT THETA-BURST STIMULATION WITH D-CYCLOSERINE AUGMENTATION FOR DEPRESSION (AIDA-DEP)- A STUDY PROTOCOL

AIDA-DEP is an ongoing multicenter randomized controlled trial in Sweden testing whether adding D-cycloserine to accelerated intermittent theta burst stimulation improves outcomes in major depressive disorder.

The aim is to test whether combining accelerated intermittent theta burst stimulation (aiTBS), an intensive form of transcranial magnetic stimulation (TMS), with the pharmacological agent D-cycloserine improves treatment outcomes in individuals with major depressive disorder. The study is a randomized, double-blind, placebo-controlled multicenter trial, with 90 participants planned over three years; the target enrollment at each center is 20 in Uppsala, 20 in Stockholm, 15 in Örebro, 20 in Västra Götaland, and 15 in Skåne. Participants will receive six aiTBS sessions per day for nine consecutive working days, augmented with either D-cycloserine or placebo. The primary outcome measure is change in MADRS score from baseline, which will be analyzed using a linear mixed model, with baseline MADRS score, sex, treatment arm, time point, and their interactions included as covariates. Secondary outcome measures include treatment response, defined as a reduction of at least 50% in MADRS score, neurophysiological measurements using fNIRS and EEG, psychiatric rating scales, a cognitive test battery, and a measure of treatment credibility (TCS); assessments are scheduled from the screening period (days -35 to -1) through days 1 to 5, days 8 to 11, day 28, and day 180. The rationale presented in the poster states that although electroconvulsive therapy is the most effective option (with a response rate of approximately 70%), its use is limited by cognitive adverse effects and the need for anesthesia; iTBS is an intervention with fewer adverse effects but a lower response rate (20% to 40%). D-cycloserine (100 mg), a partial NMDA receptor agonist, is reported to enhance neuroplasticity and to have been shown to significantly improve outcomes compared with placebo when added to TMS; as the study is ongoing, no outcome data have been presented.

Tüm WCP 2026 özetleri